Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Asia Biotech Group dengue fever peptide vaccine
- Development stage
- Preclinical
- Lead developer
- Asia Biotech Group
- Modality
- Vaccines & Immunotherapeutics, Peptides
01
Overview
Asia Biotech Group's dengue fever peptide vaccine is a preclinical synthetic peptide candidate designed to provide broad protection against all four serotypes of the dengue virus (DENV-1, DENV-2, DENV-3, and DENV-4). Developed using the company's proprietary epitope platform, the vaccine targets the viral envelope (E) protein, also known as the coat protein, which is essential for viral attachment and entry into host cells. By utilizing synthetic peptides that represent specific immunogenic epitopes of the E protein, the vaccine aims to induce a robust neutralizing antibody response and T-cell mediated immunity. This approach is intended to overcome the complexities of dengue vaccination, such as the risk of antibody-dependent enhancement (ADE), by focusing the immune response on highly conserved and protective regions of the virus.
- Other names
- dengue fever peptide vaccineDengue virus coat protein E (4 serotypes) synthetic peptide vaccine
02
Targets
DENV-1 E (Dengue virus serotype 1 envelope protein)DENV-2 E (Dengue virus serotype 2 envelope protein)DENV-3 E (Dengue virus serotype 3 envelope protein)DENV-4 E (Dengue virus serotype 4 envelope protein)
Beyond the preview
Go deeper on Asia Biotech Group dengue fever peptide vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Asia Biotech Group dengue fever peptide vaccine.